Effect of glatiramer acetate (Copaxone) given orally in human patients: interleukin-10 production during a phase 1 trial.
de Seze
J
J
Edan
G
G
Labalette
M
M
Dessaint
J P
JP
Vermersch
P
P
D000276:Adjuvants, Immunologic / Q000494:pharmacology / Q000627:therapeutic use*; D000284:Administration, Oral; D016207:Cytokines / Q000096:biosynthesis; D004311:Double-Blind Method; D000068717:Glatiramer Acetate; D006801:Humans; D016753:Interleukin-10 / Q000096:biosynthesis*; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000378:metabolism; D010455:Peptides / Q000494:pharmacology / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D016207:Cytokines; D010455:Peptides; D016753:Interleukin-10; D000068717:Glatiramer Acetate